Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 29 Aug 2017 According to an Eli Lilly media release, results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
- 13 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.